Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study
- PMID: 35397851
- PMCID: PMC8989396
- DOI: 10.1016/S0140-6736(22)00327-0
Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study
Abstract
Background: The SARS-CoV-2 variant of concern, omicron, appears to be less severe than delta. We aim to quantify the differences in symptom prevalence, risk of hospital admission, and symptom duration among the vaccinated population.
Methods: In this prospective longitudinal observational study, we collected data from participants who were self-reporting test results and symptoms in the ZOE COVID app (previously known as the COVID Symptoms Study App). Eligible participants were aged 16-99 years, based in the UK, with a body-mass index between 15 and 55 kg/m2, had received at least two doses of any SARS-CoV-2 vaccine, were symptomatic, and logged a positive symptomatic PCR or lateral flow result for SARS-CoV-2 during the study period. The primary outcome was the likelihood of developing a given symptom (of the 32 monitored in the app) or hospital admission within 7 days before or after the positive test in participants infected during omicron prevalence compared with those infected during delta prevalence.
Findings: Between June 1, 2021, and Jan 17, 2022, we identified 63 002 participants who tested positive for SARS-CoV-2 and reported symptoms in the ZOE app. These patients were matched 1:1 for age, sex, and vaccination dose, across two periods (June 1 to Nov 27, 2021, delta prevalent at >70%; n=4990, and Dec 20, 2021, to Jan 17, 2022, omicron prevalent at >70%; n=4990). Loss of smell was less common in participants infected during omicron prevalence than during delta prevalence (16·7% vs 52·7%, odds ratio [OR] 0·17; 95% CI 0·16-0·19, p<0·001). Sore throat was more common during omicron prevalence than during delta prevalence (70·5% vs 60·8%, 1·55; 1·43-1·69, p<0·001). There was a lower rate of hospital admission during omicron prevalence than during delta prevalence (1·9% vs 2·6%, OR 0·75; 95% CI 0·57-0·98, p=0·03).
Interpretation: The prevalence of symptoms that characterise an omicron infection differs from those of the delta SARS-CoV-2 variant, apparently with less involvement of the lower respiratory tract and reduced probability of hospital admission. Our data indicate a shorter period of illness and potentially of infectiousness which should impact work-health policies and public health advice.
Funding: Wellcome Trust, ZOE, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, and Medical Research Council.
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests TDS, AMV, CJS, and SO are consultants to ZOE. JW, AM, LP, SP, and JC are employees of ZOE. All other authors declare no competing interests.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9023868/bin/gr1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9023868/bin/gr2.gif)
Similar articles
-
SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.J Infect. 2023 Dec;87(6):506-515. doi: 10.1016/j.jinf.2023.08.009. Epub 2023 Sep 28. J Infect. 2023. PMID: 37777159
-
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.Lancet Infect Dis. 2022 Jan;22(1):43-55. doi: 10.1016/S1473-3099(21)00460-6. Epub 2021 Sep 1. Lancet Infect Dis. 2022. PMID: 34480857 Free PMC article.
-
Pregnancy outcomes after SARS-CoV-2 infection in periods dominated by delta and omicron variants in Scotland: a population-based cohort study.Lancet Respir Med. 2022 Dec;10(12):1129-1136. doi: 10.1016/S2213-2600(22)00360-5. Epub 2022 Oct 7. Lancet Respir Med. 2022. PMID: 36216011 Free PMC article.
-
Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.1.529): a prospective cohort study from Shenzhen, China.Lancet Microbe. 2023 Aug;4(8):e632-e641. doi: 10.1016/S2666-5247(23)00139-8. Epub 2023 Jul 14. Lancet Microbe. 2023. PMID: 37459867 Review.
-
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2. Cochrane Database Syst Rev. 2022. PMID: 35713300 Free PMC article. Review.
Cited by
-
Association between acquiring SARS-CoV-2 during pregnancy and post-acute sequelae of SARS-CoV-2 infection: RECOVER electronic health record cohort analysis.EClinicalMedicine. 2024 May 24;73:102654. doi: 10.1016/j.eclinm.2024.102654. eCollection 2024 Jul. EClinicalMedicine. 2024. PMID: 38828129 Free PMC article.
-
Microbiome in the nasopharynx: Insights into the impact of COVID-19 severity.Heliyon. 2024 May 18;10(10):e31562. doi: 10.1016/j.heliyon.2024.e31562. eCollection 2024 May 30. Heliyon. 2024. PMID: 38826746 Free PMC article.
-
From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2.Vaccines (Basel). 2024 Apr 25;12(5):459. doi: 10.3390/vaccines12050459. Vaccines (Basel). 2024. PMID: 38793710 Free PMC article. Review.
-
Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study.Vaccines (Basel). 2024 Apr 23;12(5):447. doi: 10.3390/vaccines12050447. Vaccines (Basel). 2024. PMID: 38793698 Free PMC article.
-
In Silico Analyses Indicate a Lower Potency for Dimerization of TLR4/MD-2 as the Reason for the Lower Pathogenicity of Omicron Compared to Wild-Type Virus and Earlier SARS-CoV-2 Variants.Int J Mol Sci. 2024 May 17;25(10):5451. doi: 10.3390/ijms25105451. Int J Mol Sci. 2024. PMID: 38791489 Free PMC article.
References
-
- UK Health Security Agency Omicron daily overview. 21 December 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploa...
-
- WHO Regional Office for Africa Omicron spreads but severe cases remain low in South Africa. https://www.afro.who.int/news/omicron-spreads-severe-cases-remain-low-so...
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous